Form 4: 10x Genomics CEO Serge Saxonov Reports Share Transactions

10x Genomics CEO Serge Saxonov reported the acquisition of 1,350 Class A Common Stock shares and indirect holdings through various trusts.

Summary

• Serge Saxonov, CEO of 10x Genomics, filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• The report indicates that Mr. Saxonov acquired 1,350 shares of Class A Common Stock on November 14, 2024, at a price of $0.
• The filing also shows Mr. Saxonov's indirect ownership of Class A Common Stock through several trusts, including the Andromeda Trust (27 shares), the Sirius Trust (870 shares), the Y/S Descendants' Trust (213,250 shares), and the Y/S Pot Trust (22,570 shares).
• Following these transactions, Mr. Saxonov directly owns 881,117 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing and does not indicate any positive or negative sentiment.

Industry Context

This is a routine SEC filing related to insider trading and is common for executives of publicly traded companies.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
• The reporting of indirect holdings through trusts is also a common practice for executives.

Stakeholder Impact

• This filing provides transparency to shareholders regarding the CEO's stock ownership.

Key Dates

Keywords

Form 4, Beneficial Ownership, Serge Saxonov, 10x Genomics, TXG, Class A Common Stock, Insider Trading, SEC Filing